ased with the results of
the trial and look forward to discussing the significance of our data and
our commercialization strategy in an upcoming investor roundtable, planned
for July," said Gail Page, President and CEO of Vermillion. "We also look
forward to receiving regulatory clearance from the FDA and making OVA1
available to the hundreds of thousands of women who could benefit
considerably from the test."
Vermillion will host a roundtable teleconference to address the need
for OVA1 on Tuesday, July 15. Fred Ueland, M.D., principal investigator of
the OVA1 clinical study, will serve as the keynote speaker. Conference call
details, including dial-in information and timing, are forthcoming.
About Vermillion's Ovarian Cancer Diagnostic Program
In addition to developing a diagnostic test designed to distinguish
between benign and malignant pelvic masses, Vermillion has a broad program
of ovarian cancer diagnostic tests in development. Studies are underway to
validate diagnostic tests developed to detect early-stage ovarian cancer,
predict prognosis and recurrence, and identify women considered at
high-risk for the disease.
Vermillion's comprehensive diagnostic development program is being
conducted with several leading collaborators at The Johns Hopkins School of
Medicine, The University of Texas M.D. Anderson Cancer Center,
Rigshospitalet (Copenhagen), and the University of Kentucky.
The Company's OVA1 test is part of a strategic alliance with Quest
Diagnostics to jointly develop and commercialize diagnostic tests.
Vermillion, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with
its prestigious scientific collaborators, has diagnostic programs in
oncology, hematology, cardiology and women's health. Vermillion is based in
Fremont, California. Additional iPage: 1 2 3 4 Related medicine technology :1
. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder2
. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease3
. Vermillion Receives Award From the Society of Gynecologic Oncologists4
. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles5
. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus6
. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis7
. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer8
. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer9
. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules10
. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures11
. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery